Title
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress.

Permalink
https://escholarship.org/uc/item/81h4824c

Journal
BMC nephrology, 16(1)

ISSN
1471-2369

Authors
Yeung, Catherine K
Billings, Frederic T
Claessens, Adam J
et al.

Publication Date
2015-11-03

DOI
10.1186/s12882-015-0178-2

Peer reviewed
Coenzyme $Q_{10}$ dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress

Catherine K. Yeung$^{1,2,*}$, Frederic T. Billings IV$^3$, Adam J. Claessens$^1$, Baback Roshanravan$^2$, Lori Linke$^2$, Mary B. Sundell$^5$, Suhail Ahmad$^2$, Baohai Shao$^4$, Danny D. Shen$^1$, T. Alp Ikizler$^5$ and Jonathan Himmelfarb$^2$

**Abstract**

**Background:** Coenzyme $Q_{10}$ (CoQ$_{10}$) supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure. There are no studies evaluating the safety, tolerability and efficacy of varying doses of CoQ$_{10}$ in chronic hemodialysis patients, a population subject to increased oxidative stress.

**Methods:** We performed a dose escalation study to test the hypothesis that CoQ$_{10}$ therapy is safe, well-tolerated, and improves biomarkers of oxidative stress in patients receiving hemodialysis therapy. Plasma concentrations of $F_2$-isoprostanes and isofurans were measured to assess systemic oxidative stress and plasma CoQ$_{10}$ concentrations were measured to determine dose, concentration and response relationships.

**Results:** Fifteen of the 20 subjects completed the entire dose escalation sequence. Mean CoQ$_{10}$ levels increased in a linear fashion from $704 \pm 286$ ng/mL at baseline to $4033 \pm 1637$ ng/mL, and plasma isofuran concentrations decreased from $141 \pm 67.5$ pg/mL at baseline to $72.2 \pm 37.5$ pg/mL at the completion of the study ($P<0.003$ vs. baseline and $P<0.001$ for the effect of dose escalation on isofurans). Plasma $F_2$-isoprostane concentrations did not change during the study.

**Conclusions:** CoQ$_{10}$ supplementation at doses as high as 1800 mg per day was safe in all subjects and well-tolerated in most. Short-term daily CoQ$_{10}$ supplementation decreased plasma isofuran concentrations in a dose dependent manner. CoQ$_{10}$ supplementation may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.

**Trial Registration:** This clinical trial was registered on clinicaltrials.gov [NCT00908297] on May 21, 2009.

**Keywords:** Clinical study, Coenzyme Q$_{10}$, Hemodialysis, Kidney disease, Oxidative stress

**Background**

Five hundred thousand patients in the United States receive maintenance hemodialysis (MHD) for end-stage renal disease (ESRD) [1]. Life expectancies for MHD patients are 17–34 % less than those of the general population [2]. Some of this excess mortality may be attributable to an increased risk of cardiovascular disease as a result of increased oxidative stress [3, 4]. Oxidative stress can originate from multiple sources, including the decoupling of the electron transport chain in the mitochondria and inflammation-mediated production of superoxide via NADPH-oxidase and resulting altered oxygen handling capacity.

Coenzyme $Q_{10}$ (CoQ$_{10}$) is a required component of the mitochondrial electron transport chain, where it transfers electrons from complexes 1 and 2 to complex 3. Reduction and oxidation of CoQ$_{10}$ also reduces lipid radicals and oxidizes superoxide. CoQ$_{10}$ depletion leads to inefficient electron transport, increased reactive oxygen species (ROS) production, decreased adenosine triphosphate (ATP) production, and altered mitochondrial oxidative stress [3, 4].
membrane potential [5]. CoQ10 treatment, on the other hand, improves mitochondrial coupling of respiration to oxidative phosphorylation, decreases superoxide production in endothelial cells, and may improve functional cardiac capacity in patients with congestive heart failure [6]. In addition to the effects on mitochondrial transport, CoQ10 also exerts global antioxidant effects, with the reduced form able to react directly with free radicals, wherein it is converted to the oxidized form [7]. For these reasons, CoQ10 is frequently administered as a dietary supplement in alternative and complementary therapy, but no studies have examined high dose CoQ10 tolerability and efficacy in dialysis patients, a population with increased oxidative stress [8, 9]. F2-isoprostane and isofuran concentrations, products of non-enzymatic arachidonic acid peroxidation, are considered one of the most reliable approaches for assessing systemic oxidative stress in vivo [10]. The formation of F2-isoprostanes and isofurans is differentially regulated by oxygen tension; the formation of F2-isoprostanes is favored at low oxygen tensions whereas the formation of isofurans is favored at high oxygen tensions, as occurs in the setting of mitochondrial dysfunction [11, 12]. Plasma F2-isoprostane concentrations have been shown to be two to four times higher in dialysis patients than in age- and gender-matched healthy subjects [13, 14], consistent with the increased oxidative burden in this population. Plasma isofuran concentrations have not previously been reported in dialysis patients.

The present study tested the hypothesis that oral CoQ10 administration is safe, well-tolerated, and decreases oxidative stress in MHD patients, with the additional goals of determining the maximum well-tolerated dose of CoQ10.

Methods

Study design

We performed an open label, dose-escalation study (Fig. 1) to evaluate the safety and tolerability of CoQ10 in HD patients using a commercially available CoQ10 chewable wafer (Vitaline Formulas, Wilsonville, OR).

![CoQ10 dose escalation study design](image)

**Fig. 1** CoQ10 dose escalation study design. *Measurement of plasma CoQ10, comprehensive metabolic panel, creatine phosphokinase, and oxidative stress biomarkers

**Study population**

End stage renal disease patients, between the ages of 18 and 85 years, receiving thrice weekly dialysis using high-flux dialyzers, with a life expectancy of >1 year, and a baseline plasma F2-isoprostane concentration greater than or equal to 50 pg/ml were eligible for study. Twenty MHD subjects were enrolled from two university medical centers. All subjects provided written informed consent that was approved by the University of Washington and the Vanderbilt University Institutional Review Boards. All study procedures were conducted in accordance with Helsinki Declaration of 1975 (as revised in 2000).

Subject exclusion criteria included: history of poor adherence to MHD or medical regimen, AIDS (HIV seropositivity was not an exclusion criteria), active malignancy excluding basal cell carcinoma of the skin, gastrointestinal dysfunction requiring parenteral nutrition, kidney transplant <6 months prior to study entry or anticipated live donor kidney transplant, current use of vitamin E supplements >60 IU/day, vitamin C supplements >150 mg/day, current use of l-carnitine or other antioxidant or nutritional supplements, initiation of hemodialysis within 90 days prior to study enrollment, hospitalization within the past 60 days, dialysis with a tunneled catheter as a temporary vascular access, and a history of a major atherosclerotic event (defined as myocardial infarction, urgent target-vessel revascularization, coronary artery bypass surgery, or stroke) within six months.

Plasma samples from healthy control subjects (n = 10) were randomly selected from the Kidney Research Institute biorepository. Healthy control subjects had normal kidney function and were not taking statin medications. Healthy control subjects were not matched for age, race, or gender with subjects receiving CoQ10 supplementation. The control subjects were younger, more likely to be female, and less likely to be taking a statin than the dialysis subjects.

With a sample size of 20 subjects, we predicted that we would have at least 94 % power to detect a 45 % change in plasma F2-isoprostane levels after CoQ10 administration (estimated mean plasma F2-isoprostane concentrations in MHD patients = 96 pg/mL, with a standard deviation of 49 pg/mL), assuming a 2-sided, 0.05 alpha level using a paired t-test approach.

**CoQ10 dose escalation**

Subjects were administered 300 mg CoQ10 for 14 days and then 600, 1200, and 1800 mg CoQ10 daily, each for 14 days. Subjects returned to the clinic at the end of each dosing period and spontaneously reported adverse events were recorded at every visit. Blood samples were collected at baseline, and after each 14-day course of treatment for determination of comprehensive metabolic
panel (electrolytes, blood urea nitrogen, creatinine, glucose, albumin, total protein, calcium, alkaline phosphatase, ALT, AST, total bilirubin), creatine phosphokinase (CPK), F₂-isoprostane and isofuran concentrations. Blood samples for High Density Lipoprotein (HDL) apoA-1 Met(O) were collected at baseline and following 1200 mg dosing period. All blood samples were immediately chilled, and then centrifuged within one hour of collection at 2500 RPM, 4 °C, for 15 min. Plasma (heparinized) was removed and stored at −80 °C until analysis. Ten subjects participated in an additional study in which CoQ₁₀ levels were measured prior to and immediately following standard HD to assess the effect of HD on plasma CoQ₁₀ concentrations. CoQ₁₀ concentrations were also measured in the plasma of the 10 unmatched healthy control subjects. Access to the remaining samples may be granted by contacting the corresponding author.

**Assays**

For CoQ₁₀ measurement, plasma samples were thawed on ice, and a 100 µL aliquot was mixed with 200 µL ice cold 1-propanol containing Coenzyme Q₉ (CoQ₉) and CoQ₉H₂ as internal standards. Precipitated proteins were removed by cold centrifugation, and the supernatant injected directly onto the LC-MS/MS for analysis. Samples in the autosampler were held at 4 °C until injection. Chromatography of the analytes was accomplished using an Agilent 1200-series LC system equipped with a Zorbax SB-C₁₈ column (30 mm x 2.1 mm x 3.5 µM particle size) that was maintained at 40 °C. The mobile phase consisted of a binary gradient of methanol and 5 mM ammonium formate pumped at a flow rate of 0.8 mL/min. The MS/MS was operated in positive ESI mode with nitrogen as drying gas at a flow of 10 L/min and 350 °C, and with nitrogen nebulizer gas set at 35 psi. The monitored transitions for CoQ₁₀H₂, CoQ₁₀, CoQ₉H₂ and CoQ₉ were 882.7 → 197.1, 863.7 → 197.1, 814.7 → 197.1, and 795.6 → 197.1 respectively. Method validation, including stability of analytes and internal standards, and comparisons to established methods are detailed in reference [15].

For F₂-isoprostane and isofuran measurements, internal standard [²H₅]-15-F₂T-isoprostane was added to each plasma sample prior to C-18 and silica solid phase extraction, thin layer chromatography, and derivatization to penta-fluorobenzyl ester, trimethylsilyl ether derivative [16]. GC/NICI-MS was performed (Agilent 5973) using 15 m x 0.25 µm thick fused silica capillary columns (J and W Scientific). The major ion generated was m/z 569 carboxylate anion [M-181 (M-CH₂CN,F₂)]. The corresponding ion generated from the [²H₅]-15-F₂T-isoprostane internal standard was m/z 573, and the isofuran ion was m/z 585.

For Met(O) measurement, HDL was isolated, digested and oxidation of Met residues in apoA-I of HDL was quantified by isotope dilution mass spectrometry (MS) and selective reaction monitoring (SRM) on a Thermo TSQ Vantage coupled to a Waters nanoACQUITY UltraPerformance liquid chromatography system as previously described [17].

Comprehensive metabolic panel and CPK measurements were performed in the CLIA-certified hospital laboratories of University of Washington Medical Center and Vanderbilt University Medical Center. Plasma IL-6 was measured using a commercial kit according to the manufacturer’s protocol (R&D Systems, Minneapolis MN).

**Data analysis**

Mean baseline values and change from baseline were determined for CoQ₁₀ concentrations, all safety endpoints (comprehensive metabolic panel, CPK, electrocardiogram results, physical examination findings), and efficacy measures (oxidative stress biomarker concentrations). Each of these parameters was analyzed via one-way repeated measures analysis of variance to determine the presence or absence of dose-related differences. In addition, mixed effects modeling was used to test the effect of increased CoQ₁₀ dose and duration with fixed effect of time (dose), random subject effect, and an unstructured repeated covariance type. Study subject concentrations of CoQ₁₀, F₂-isoprostanes, and isofurans were also compared to concentrations in non-dialysis historical control subjects. The primary analysis included all subjects. Subgroup analyses were conducted in statin treated (n = 6) and non-statin treated (n = 14) subjects. Spearman’s correlation coefficients were used to assess correlations between plasma CoQ₁₀ concentrations and oxidative stress biomarkers. Two-tailed P-values ≤ 0.05 were considered significant in all analyses. When appropriate, corrections were made for multiple comparisons. Statistical analysis was conducted using STATA 11.0 and SAS 9.1 (SAS Institute, Cary, NC, USA). Data is expressed as mean ± standard deviation unless otherwise specified.

**Results**

Twenty subjects were recruited for the study, fifteen of whom completed the entire dose escalation protocol (Fig. 2). The mean age of subjects was 58 years with 8 females studied. Average length of time on dialysis was 8.0 ± 8.9 years (range 0.7 to 29.4 years). Seven subjects were taking statin medications. Three subjects discontinued study participation due to abdominal pain or nausea; one during the 300 mg/day period, one during the 1200 mg/day period, and one after the 1800 mg/day period. One subject discontinued participation after an unrelated elevation in INR (international normalized ratio).
ratio), and one subject discontinued participation after damaging a tooth from chewing the CoQ10 wafer. Three subjects reported stomach discomfort at the 1800 mg/day dose but completed the study. One subject was found expired at home 22 days after completing the study. This death was attributed to natural causes and was deemed to be unrelated to study participation.

**Plasma CoQ10 concentrations**

Mean plasma total CoQ10 levels at baseline (prior to a mid-week dialysis session) were 704 ± 286 ng/mL, significantly lower than CoQ10 levels in healthy control patients (1385 ± 640 ng/mL, P = 0.0014). Plasma CoQ10 concentrations increased linearly with escalation of CoQ10 dose (Fig. 3). At the end of the 1800 mg/day dosing period, total CoQ10 plasma concentrations averaged 4032 ± 1637 ng/mL (P < 0.001 compared to baseline and to healthy controls). The CoQ10 redox ratio (CoQ10H2:CoQ10) increased from 14 ± 7.4 at baseline to 22 ± 9 after supplementation (P = 0.013). Despite this increase, the redox ratio remained significantly less than that observed in healthy controls (41 ± 12, P < 0.001, Fig. 3). Statin using (n = 6) and non-using (n = 14) subjects had similar plasma concentrations of CoQ10 and CoQ10H2:CoQ10 ratios at baseline and at the end of the study (3438 ± 1899 ng/mL, redox ratio 25.7 ± 9.4 in statin users vs. 4080 ± 1467 ng/mL, redox ratio 18.8 ± 6.5 in statin non-users at the end of the study; P = 0.31 for CoQ10 plasma concentration, P = 0.10 for redox ratio). Plasma CoQ10 levels measured just before and immediately after hemodialysis did not differ significantly (Fig. 4), indicating that hemodialysis does not clear the lipophilic CoQ10 from blood or acutely alter the circulating pool of CoQ10 (p = 0.72).

**Effects of CoQ10 supplementation on F2-isoprostanes and Isofurans**

Baseline F2-isoprostane and isofuran levels were 66.9 ± 24.9 pg/ml and 141 ± 67.5 pg/ml respectively, notably higher than levels observed in 140 historic control patients not on dialysis (42.5 ± 32.6 pg/mL F2-isoprostanes, P = 0.002 and 57.0 ± 52.9 pg/mL isofurans, P < 0.001) [18]. During CoQ10 dose escalation, F2-isoprostane concentrations did not change compared to baseline (P = 0.92). Plasma isofuran concentrations, however, decreased following the 1200 mg (112.8 ± 72.9 pg/ml) and 1800 mg (72.8 ± 37.5 pg/ml) dosing periods (P < 0.001, effect of dose escalation on isofurans, Fig. 5a-c). Isofuran concentrations following 1800 mg/day CoQ10 dosing were 45.1 ± 8.1 % lower than baseline concentrations (P = 0.003). In addition, the ratio of isofuran concentrations to F2-isoprostane concentrations decreased from 2.56 ± 2.26 to 1.07 ± 0.56 during CoQ10 dose escalation (P = 0.01), a ratio similar to that observed in non-dialysis control subjects (1.53 ± 1.31, P = 0.16). Consistent with the effect of CoQ10 dose escalation on
isofuran concentrations and isofuran:F$_2$-isoprostane ratios, plasma concentrations of CoQ$_{10}$ were inversely correlated with isofuran concentrations and isofuran:F$_2$-isoprostane ratios (CoQ$_{10}$ isofuran correlation coefficient = $-0.29$, $P = 0.02$; CoQ$_{10}$ isofurans:F$_2$-isoprostane ratio correlation coefficient = $-0.28$, $P = 0.02$). There was no correlation between plasma concentrations of F$_2$-isoprostanes and plasma CoQ$_{10}$ concentrations ($P = 0.62$, Fig. 5d–f).

**Effects of CoQ$_{10}$ supplementation on interleukin-6 (IL-6)**

Baseline mean IL-6 concentration was 11.2 ± 8.1 ng/ml. During CoQ$_{10}$ dose escalation, IL-6 levels did not change significantly (15.7 ± 18.9 ng/mL at 1800 mg CoQ$_{10}$, $P = 0.56$), and no association was observed between IL-6 levels and plasma CoQ$_{10}$ levels ($P = 0.20$) (Fig. 6a and b).

**Effects of CoQ$_{10}$ supplementation on apoprotein A-1 (apoA-1) methionine oxidation (Met(O))**

Oxidation of Met residues 86, 112, or 148 in apoA-1 was not different following the 1200 mg CoQ$_{10}$ dosing period, as compared to baseline apoA-1 Met oxidation (Fig. 7).

**Safety and tolerability**

Six subjects complained of nausea and abdominal pain during the course of the study. One of these subjects made this complaint during the 300 mg dosing period, two following the 1200 mg dosing period, and three following the 1800 mg dosing period. Three of these subjects discontinued CoQ$_{10}$ treatment, but the other three subjects continued taking CoQ$_{10}$ despite reporting nausea and abdominal pain. Gastrointestinal complaints resolved after discontinuation of CoQ$_{10}$. One subject (non-statin user) was found to have a CPK concentration of 2918 U/L following the 600 mg dosing period but was known to participate in competitive athletics and did not report any myalgia. He remained in the study and following the 1200 mg period his CPK level
returned to 311 U/L (similar to his baseline concentration). Overall mean CPK concentrations did not change in the study cohort during CoQ_{10} dose escalation. CoQ_{10} dose escalation did not affect blood pressure.

Discussion
In this dose escalation study we found oral administration of CoQ_{10} to be safe and well-tolerated at doses under 1800 mg/day. Three of the 5 of the adverse events occurred in subjects receiving more than 1200 mg daily, and only 3 of 6 subjects experiencing adverse effects withdrew from the study. Plasma CoQ_{10} levels increased linearly with dose, suggesting that the chewable wafer used in this study has consistent bioavailability. In addition, our data indicated that CoQ_{10} may reduce systemic oxidative stress in MHD patients in a dose-dependent manner.

CoQ_{10} has been studied extensively in healthy populations and patients with cognitive impairment. In these populations, CoQ_{10} has also been well tolerated. MHD patients are subject to elevated inflammation and oxidative stress as a result of ineffective clearance of uremic toxins, especially middle molecules (molecular weight 300–20,000 Da) [19] that include circulating cytokines. We have previously observed that MHD patients have 63 % higher concentrations of F_{2}-isoprostanes than healthy controls [9], and a reduction in oxidative stress has been associated with better outcomes in MHD patients. A study by Sakata et al. evaluated the efficacy of a low oral dose of CoQ_{10} (100 mg daily) for 6 months in Japanese MHD patients and demonstrated that CoQ_{10} partially suppressed advanced oxidation protein product accumulation [20]. Singh et al. also demonstrated a benefit of CoQ_{10} in CKD; subjects who received 60 mg of CoQ_{10} three times daily had reduced serum creatinine and urea concentrations, increased creatinine clearance, and urine output compared with controls [21]. The doses used in Sakata and Singh studies were lower than those typically used in other studies (300–1200 mg daily); higher doses of CoQ_{10} may be required to substantively reduce oxidative stress in the MHD population. The present study is the first study to evaluate the safety and tolerability of high dose CoQ_{10} in a population receiving MHD.

CoQ_{10} dose escalation reduced plasma concentrations of isofurans but not F_{2}-isoprostanes or HDL apoA-1 Met oxidation. To our knowledge, this is the first in vivo study in any patient population to demonstrate that plasma concentrations of isofurans are modifiable by any therapeutic antioxidant strategy. Our results are consistent with previously published unrelated studies, that show that plasma F_{2}-isoprostane concentrations are significantly increased in patients undergoing maintenance HD compared with healthy subjects (published healthy controls: 37.6 pg/mL [14], subjects at baseline in this study: 65 pg/mL, after 1800 mg CoQ10: 72 pg/mL). In contrast, our subjects who also had elevated concentrations of isofurans at baseline (0.145 ng/mL) compared with healthy subjects (0.071 ng/mL) [22] demonstrated near-normalization after maximal supplementation (0.078 ng/mL). The generation of isofurans and F_{2}-isoprostanes is regulated by the availability of oxygen; in cellular environments with relatively low oxygen availability, F_{2}-isoprostanes are generated from ROS, while
isofurans are preferentially generated in environments with relatively high oxygen availability. In vivo, isofuran generation is observed during inhalation of high concentrations of oxygen in healthy subjects and in tissues with low consumption of oxygen such as the substantia nigra of Parkinson’s patients [11]. Mitochondrial dysfunction observed in Parkinsonism or ESRD, may lead to high cellular oxygen tension since dysfunctional mitochondria consume little oxygen. In this environment ROS formation preferentially increases the generation of isofurans but not F₂-isoprostanes. CoQ₁₀ transfers electrons from complexes 1 and 2 to complex 3 in the mitochondrial electron transport chain. The suppression of isofuran generation observed with CoQ₁₀ dose escalation is consistent with the idea that CoQ₁₀ improves mitochondrial function in MHD patients and reduces the generation of ROS.

In order to differentiate the effects of CoQ₁₀ on mitochondrial coupling versus direct antioxidant effect, we evaluated the effect of CoQ₁₀ supplementation on ApoA-1 Met oxidation, which is selective for inflammation-mediated oxidative damage by myeloperoxidase (MPO). The lack of effect of CoQ₁₀ escalation on apoA-1 Met oxidation in circulating HDL suggests the salutary effect of CoQ₁₀ may be due to improved local mitochondrial function rather than a systemic anti-oxidant effect. The reduction of HDL-associated lipid hydroperoxides to the corresponding lipid hydroxides is responsible for specific oxidized Met residues (Met(O) 86 and Met(O) 112) in apoA-I, the major HDL protein [17]. In addition, hydrogen peroxide and hypochlorous acid (HOCl), a strong oxidant produced by the phagocyte heme enzyme myeloperoxidase may selectively oxidize Met112 and Met148 in apoA-I [23, 24]. In addition to the lack of effect of CoQ₁₀ supplementation on ApoA-1 Met oxidation, no significant change in IL-6, a pro-inflammatory cytokine (11.2 ± 8.1 pg/mL at baseline; 15.7 ± 18.9 pg/mL at study conclusion (p = 0.56), in comparison to unrelated healthy controls with a median IL-6 concentration: 3.8 pg/mL) [25], was observed during this study, providing more presumptive evidence that the actions of CoQ₁₀ are not due to a global anti-inflammatory effect. Taken together, our observations support the hypothesis that CoQ₁₀ supplementation reduces mitochondrial oxidative stress, rather than by increasing general antioxidant or anti-inflammatory capacity. However, we cannot rule out some contribution of general antioxidant effect to the observed reduction in oxidative stress markers.

This study has several limitations that are inherent to fixed-sequence dose escalation studies. The dosing design does not allow us to fully attribute the observed effect on markers of oxidative stress to escalated dose or duration of CoQ₁₀ supplementation and were unable to control for the effects of disease progression during the study. This study was conducted in patients undergoing thrice weekly hemodialysis, and did not include patients receiving alternate methods of dialysis, including peritoneal dialysis or daily dialysis. Since the exposures to uremic toxins in patients receiving other types of dialysis or dialytic regimens differ from our study population, we are unable to generalize our findings to these other dialysis regimens. The study examined relatively short-term effects of CoQ₁₀ administration. Longer term CoQ₁₀ supplementation could have some safety concerns, as CoQ₁₀ could precipitate drug-drug interactions—in animal studies, CoQ₁₀ supplementation has been shown to affect metabolism of theophylline [26], and in vitro, affect transport by P-glycoprotein, an intestinal drug transporter [27]. CoQ₁₀ supplementation could also alter the oral bioavailability of digoxin and verapamil, both P-glycoprotein substrates.

In summary, CoQ₁₀ appears to be safe and well tolerated in subjects receiving MHD and may reduce oxidative stress by improving mitochondrial function. Further studies are needed to investigate the potential metabolic and clinical benefits associated with longer term CoQ₁₀ supplementation.

Conclusions

Coenzyme Q₁₀ supplementation improves mitochondrial coupling of respiration to oxidative phosphorylation, and decreases superoxide production in endothelial cells. CoQ₁₀ may be especially beneficial in patients undergoing chronic hemodialysis, a population subject to increased oxidative stress. This is the first in vivo study in any patient population to demonstrate that plasma concentrations of isofurans are modifiable by any therapeutic antioxidant strategy and suggests that CoQ₁₀ may improve mitochondrial function and decrease oxidative stress in patients receiving hemodialysis.

Abbreviations

AIDS: Acquired immune deficiency syndrome; apoA-1: Apolipoprotein A-1; ATP: Adenosine Triphosphate; CoQ₉: Coenzyme Q9; CoQ₁₀: Coenzyme Q10; CPK: Creatine phosphokinase; ESRD: End stage renal disease; HD: Hemodialysis; HDL: High density lipoprotein; IL-6: Interleukin-6; INR: International normalized ratio; Met(O): Oxidized methionine; MHD: Maintenance hemodialysis; ROS: Reactive oxygen species.

Competing interests

No competing financial or non-financial interests exist.

Authors’ contributions

CKY participated in conduct and design of the study and data analyses, drafted and revised the manuscript. FTB conducted the data analysis and participated in drafting the manuscript and revising it critically for important intellectual content. AJC was responsible for sample analysis and assay development. BR participated in drafting the manuscript and revising it critically for important intellectual content. LL and MBS were critical in study development. BS conducted laboratory analyses and provided critical intellectual content. DDS and TAI provided oversight, assisted with
conduct and design of the study, and revised the drafted manuscript for important intellectual content. JH conceptualized the study, provided oversight for the study design and conduct, and participated in drafting the manuscript and revising it critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

These studies were supported by grants from the National Institute of Health NCCAM R21 AT004265-03, NCATS Grant K22 TR000421 and UL1TR000445, National Institute of Environmental Health Sciences P30 ES00267, National Institute of General Medical Sciences K23 GM102676, and National Heart, Lung and Blood Institute R01 HL070938. CKY would like to acknowledge the Norman S. Coplon Extramural Grant Program by Satellite Healthcare, a not-for-profit renal care provider.

Author details

1 Department of Pharmacy, University of Washington School of Pharmacy, Box 357630, Seattle, WA 98195, USA. 2 Department of Medicine, Kidney Research Institute, University of Washington School of Medicine, Box 35960, Seattle, WA 98195, USA. 3 Division of Critical Care Medicine, Department of Anesthesiology, Vanderbilt University Medical Center, 1211 21st Avenue South, 526 Medical Arts Building, Nashville, TN 37205, USA. 4 Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Box 35855, Seattle, WA, USA. 5 Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, South, S-323 Medical Center North, Nashville, TN 37232, USA.

Received: 1 April 2015 Accepted: 29 October 2015

Published online: 03 November 2015

References

1. U S Renal Data System, USRDS. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2013. www.usrds.org.
2. MEDPAC. A Data Book: Healthcare Spending and the Medicare Program. 2009.
3. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48(6):752–60. doi:10.1053/j.ajkd.2006.08.015.
4. Kuchta A, Pacanis A, Kortas-Stempak B, Cwiklinska A, Zietkiewicz M, Renke M, et al. Estimation of oxidative stress markers in chronic kidney disease. Kidney Blood Press Res. 2011;34(1):12–9. doi:10.1159/000315208.
5. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephropathy (Carlton). 2012;17(4):1–11. doi:10.1111/j.1440-1797.2012.01572.x.
6. Beyer RE. The participation of coenzyme Q in free radical production and antioxidation. Free Radic Biol Med. 1990;8(6):545–65.
7. Kandar R. The ratio of oxidized and reduced forms of selected antioxidants as a possible marker of oxidative stress in humans. Biomed Chromatogr. 2010. doi:10.1002/bmc.3529.
8. Himmelheber J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62(5):1524–38. doi:10.1046/j.1523-1755.2002.00600.x.
9. Ramos LF, Shintani A, Ikizler TA, Himmelheber J. Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. J Am Soc Nephrol. 2008;19(5):698–708. doi:10.1681/ASN.2007030355.
10. Kadiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study I: are oxidation products of lipids, proteins, and DNA markers of CC4 poisoning? Free Radic Biol Med. 2005;38(6):698–710. doi:10.1016/j.freeradbiomed.2004.09.017.
11. Fessel JP, Hulett C, Powell S, Roberts 2nd LJ, Zhang J. Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson’s disease and with dementia with Lewy body disease. J Neurochem. 2003;85(3):645–50.
12. Fessel JP, Porter NA, Moore KP, Sheller JR, Roberts 2nd LJ. Discovery of lipid peroxidation products formed in vivo with a substituted tetraldehydefuran ring (isofuran) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A. 2002;99(26):16713–8. doi:10.1073/pnas.252649099.
13. Handelman GJ, Walter MF, Adhikara R, Gross J, Dallal GE, Levin NW, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001;59(5):1960–6. doi:10.1046/j.1523-1755.2001.0050051960.x.
14. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58(3):190–7.
15. Claessens AJ, Young CK, Rider LJ, Phillips BR, Himmelheber J, Shen DD. Rapid and sensitive analysis of reduced and oxidized coenzyme Q10 in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and application to studies in healthy human subjects. Ann Clin Biochem. 2013.
16. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2(12):2211–6. doi:10.1038/nprot.2007.365.
17. Shao B, Cavaglione G, Brot N, Oda MN, Heinecke JW. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A. 2008;105(34):12224–9. doi:10.1073/pnas.0802052105.08020505.
18. Billings FT 4th. Intraoperative normoxia, oxidative damage, and organ injury following cardiac surgery. Shock. 2015;43(1):24.
19. Babb AL, Ahmad S, Bergstrom J, Scribner BH. The middle molecule hypothesis in perspective. Am J Kidney Dis. 1981;11(1):46–50.
20. Sakata T, Furuya R, Shimazu T, Odamaki M, Ohkawa S, Kumagai H. Coenzyme Q10 administration suppresses both oxidative and antioxidative markers in hemodialysis patients. Blood Purif. 2008;26(4):371–8. doi:10.1159/000135055.
21. Singh RB, Kumar A, Niaz MA, Singh RG, Gurtari S, Singh VP, et al. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in patients with End-stage renal failure. J Nutr Environ Med. 2003;13(1):13–22.
22. Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-isoprostanes and isofurans using gas chromatography–mass spectrometry. Free Radic Biol Med. 2013;59:36–44. doi:10.1016/j.freeradbiomed.2012.09.030.
23. Shao, Heinecke JW. Using tandem mass spectrometry to quantify site-specific chlorination and nitration of proteins: model system studies with high-density lipoprotein oxidized by myeloperoxidase. Methods Enzymol. 2008;440:33–63. doi:10.1016/S0076-6879(07)00803-8.
24. von Eckardstein A, Walter M, Holz H, Benninghoven A, Assmann G. Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III. J Lipid Res. 1991;32(9):1465–76.
25. Kamimura MA, Draitse SA, Dalboni MA, Cendoroglo M, Avesani CM, Manfredi SR, et al. Serum and cellular interleukin-6 in haemodialysis patients: relationship with energy expenditure. Nephrol Dial Transplant. 2007;22(9):339–44.
26. Baskaran R, Shanmugam S, Nagayya-Srinan S, Kim JH, Leong TC, Yong CS, et al. The effect of coenzyme Q10 on the pharmacokinetic parameters of theophylline. Arch Pharm Res. 2008;31(7):938–44. doi:10.1007/s12272-009-0046-5.
27. Itagaki S, Ochiai A, Kobayashi M, Sugawara M, Hirano T, Iseki K. Interaction of coenzyme Q10 with an arterial drug transporter P-glycoprotein. J Agric Food Chem. 2008;56(16):6923–7. doi:10.1021/jf800992p.